Metabolic research comparison
Retatrutide vs Tirzepatide
A source-reviewed comparison of receptor design, published obesity trials, regulatory status and the limits of cross-trial interpretation. No completed head-to-head randomized trial establishes that one is superior to the other.
Editorial answer
The short answer
Retatrutide remains investigational; tirzepatide is the active ingredient in FDA-approved finished medicines. Published percentages come from separate protocols and must not be ranked as if they were a direct comparison.
Research and evidence interpretation only. No usage or dosing guidance.Structured comparison
Compare like with like
Every difference includes an interpretation note so a molecular or protocol distinction is not converted into a marketing claim.
Swipe horizontally to compare every column
| Question | Retatrutide | Tirzepatide | Editorial interpretation |
|---|---|---|---|
| Receptor design | Single-molecule GIP, GLP-1 and glucagon receptor agonist | Single-molecule GIP and GLP-1 receptor agonist | Mechanism count does not predict clinical superiority by itself. |
| Published obesity evidence used here | Phase 2 randomized trial; 338 adults; 48 weeks | SURMOUNT-1 Phase 3 randomized trial; 2,539 adults; 72 weeks | Different populations, durations, estimands and dose-escalation protocols. |
| Mean body-weight result | Up to −24.2% at 48 weeks in the highest studied group; placebo −2.1% | −15.0%, −19.5% and −20.9% at 72 weeks across 5, 10 and 15 mg groups; placebo −3.1% | These are within-trial results, not a retatrutide-versus-tirzepatide effect estimate. |
| U.S. regulatory status | Investigational and not FDA approved as of the review date | FDA-approved finished products; current Zepbound label includes chronic weight management and obesity-associated OSA | Catalog research material is not the approved finished medicine. |
| Evidence maturity | Phase 2 publication plus 2026 Phase 3 sponsor topline announcements; full peer-reviewed obesity Phase 3 reports remain the preferred source | Multiple Phase 3 publications and current FDA prescribing information | Sponsor topline results are tracked but not treated as peer-reviewed evidence. |
| Catalog interpretation | Research material; no clinical-use inference | Research material; cannot claim equivalence to Zepbound or Mounjaro | Lot identity and quality require product-specific analytical records. |
Evidence cards
What the linked records actually report
Findings remain attached to the study population, experimental model and source type.
The published 48-week trial reported dose-dependent weight change up to −24.2% versus −2.1% with placebo.
Phase 2, separate protocol; not a head-to-head tirzepatide comparison.Open source ↗The 72-week trial reported mean changes of −15.0%, −19.5% and −20.9% versus −3.1% with placebo.
Phase 3, different population and duration; cross-trial ranking is invalid.Open source ↗Lilly reports retatrutide Phase 3 topline results but continues to state that it is investigational and not FDA approved.
Sponsor status record, not a substitute for a peer-reviewed full report or regulatory review.Open source ↗Translation boundary
What this comparison cannot establish
- That the larger numerical percentage in one trial proves superiority.
- That a catalog peptide has the formulation, exposure, safety or efficacy of a trial drug.
- That Phase 3 topline announcements contain enough detail for independent benefit–risk assessment.
Sources
References used for this comparison
- 01Phase 2 RCT
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, et al. N Engl J Med. 2023;389:514–526. PMID 37366315.
- 02Phase 3 RCT
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, et al. N Engl J Med. 2022;387:205–216. PMID 35658024.
- 03FDA record
ZEPBOUND (tirzepatide) prescribing information
U.S. FDA. Revised 2026. NDA 217806.
- 04Sponsor status record
What to know about retatrutide
Eli Lilly and Company. Medically reviewed; updated July 2026.
Editorial analysis
Read the product-specific source reviews
These articles expand individual identity, trial and evidence questions without changing the comparison conclusions above.
Retatrutide Triple Agonism: What the Phase 2 Trial Found—and Did Not Prove
A close reading of retatrutide’s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.
Read source review →Retatrutide Development Status in 2026: An Evidence Map for Researchers
A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.
Read source review →Tirzepatide Dual GIP/GLP-1 Signaling: Mechanism and Trial Endpoints Explained
An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data…
Read source review →Tirzepatide in 2026: Approved Drug Evidence vs Research-Use Material
Why an FDA-approved tirzepatide medicine, a compounded product and a research-use catalog material are not interchangeable evidence categories.
Read source review →Comparison FAQ
Questions this page is designed to answer
Has retatrutide been compared directly with tirzepatide in a completed randomized trial?
No completed published head-to-head randomized trial was identified for this review. The commonly quoted weight-change values come from separate studies.
Is retatrutide FDA approved?
No. Lilly continued to describe retatrutide as investigational and not FDA approved at the September 1, 2026 review date.
Does tirzepatide approval apply to catalog tirzepatide material?
No. Approval applies to named finished medicines with controlled formulations, manufacturing, labeling and quality systems.
Continue researching